Brain+

0,097

DKK

0 %

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Mindre end 1K følgere

0%

+3,2%

+21%

-4,63%

-19,67%

-52,05%

-95,99%

-

-96,49%

Brain + er aktiv i medicinalindustrien. Virksomheden har specialiseret sig i forskning og udvikling til behandling af demens og Alzheimers. Produktporteføljen omfatter f.eks. Kognitiv stimuleringsterapi. Forretningen drives med den største tilstedeværelse i Europa.

Markedsværdi

20,57 mio. DKK

Aktieomsætning

1,68 t DKK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

ViserAlle indholdstyper

Selskabsmeddelelsefor 57 minutter siden

Brain+ A/S: Brain+ restructures to reduce OPEX by 35%, maintaining €1M ARR target for end 2025 and now expecting break-even by mid-2026, and announces 50% secured intended Rights Issue

Selskabsmeddelelse31.12.2024, 13.30

Brain+ A/S: Brain+ announces change of Certified Advisor

Pressemeddelelse10.12.2024, 07.45

Brain+ A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse5.12.2024, 07.51

Brain+ A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality

Pressemeddelelse21.11.2024, 14.30

Brain+ A/S: Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities

Pressemeddelelse1.11.2024, 10.57

Brain+ A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant

Pressemeddelelse21.10.2024, 09.54

Brain+ A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy

Pressemeddelelse11.10.2024, 07.04

Brain+ A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions

Selskabsmeddelelse7.10.2024, 09.50

Brain+ A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue

Pressemeddelelse2.10.2024, 08.32

Brain+ A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market

Selskabsmeddelelse1.10.2024, 10.11

Brain+ A/S: Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions

Pressemeddelelse1.10.2024, 07.23

Brain+ A/S: Ayla - your CST Assistant has been registered in the UK as a certified Medical Device Software for dementia therapy

Pressemeddelelse25.9.2024, 08.43

Brain+ A/S: Brain+ confirms imminent commercial launch of Ayla - your CST Assistant as a medical device in the UK

Pressemeddelelse23.9.2024, 10.15

Brain+ A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization

Selskabsmeddelelse20.9.2024, 06.43

Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4%

Selskabsmeddelelse17.9.2024, 08.46

Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4

Pressemeddelelse13.9.2024, 08.33

Brain+ A/S: Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027

Selskabsmeddelelse13.9.2024, 07.08

Brain+ A/S announces the exercise price for its warrants of series TO 4

Pressemeddelelse5.9.2024, 07.30

Brain+ A/S: First patient enrolled in a clinical trial to evaluate Brain+' next generation cognitive training technology for Mild Cognitive Impairment

Pressemeddelelse3.9.2024, 06.30

Brain+ A/S: Results from UK study of the CST-Assistant show clinical relevance, cost-benefit and product-market fit

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.